[
  {
    "ts": null,
    "headline": "These Are The Worst 25 Stocks to Own in February",
    "summary": "Biogen stock tends to disappoint in February",
    "url": "https://finnhub.io/api/news?id=4ea5354df6101b8335eae9361e6c50048afe8d2d0303349a30e64ba88dde8e64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770148649,
      "headline": "These Are The Worst 25 Stocks to Own in February",
      "id": 138345699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Biogen stock tends to disappoint in February",
      "url": "https://finnhub.io/api/news?id=4ea5354df6101b8335eae9361e6c50048afe8d2d0303349a30e64ba88dde8e64"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?",
    "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=ea326712da9da0039dd6ef2022190278c289210588d05099da4f4ea4b49d90db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770127204,
      "headline": "Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?",
      "id": 138342698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=ea326712da9da0039dd6ef2022190278c289210588d05099da4f4ea4b49d90db"
    }
  },
  {
    "ts": null,
    "headline": "Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today",
    "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.",
    "url": "https://finnhub.io/api/news?id=b3b453904ddbd62f9969e046b213d0fe77db6d251c140769986ac7e816b13d29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770125404,
      "headline": "Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today",
      "id": 138342699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.",
      "url": "https://finnhub.io/api/news?id=b3b453904ddbd62f9969e046b213d0fe77db6d251c140769986ac7e816b13d29"
    }
  },
  {
    "ts": null,
    "headline": "CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?",
    "summary": "CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.",
    "url": "https://finnhub.io/api/news?id=048ef9c6933d20140786663c8c565fe02b1ca1e1b7360358b901c285086dc586",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770125400,
      "headline": "CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?",
      "id": 138342700,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.",
      "url": "https://finnhub.io/api/news?id=048ef9c6933d20140786663c8c565fe02b1ca1e1b7360358b901c285086dc586"
    }
  },
  {
    "ts": null,
    "headline": "WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager",
    "summary": "WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases.",
    "url": "https://finnhub.io/api/news?id=53bf58aee610b62d2a76e2a41fe8a27cd81adfc2cd66bdbebaef6680211cc487",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770088920,
      "headline": "WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager",
      "id": 138338567,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases.",
      "url": "https://finnhub.io/api/news?id=53bf58aee610b62d2a76e2a41fe8a27cd81adfc2cd66bdbebaef6680211cc487"
    }
  }
]